Skip to main content

Advertisement

SpringerLink
Log in

Is cotrimoxazole prophylaxis against Pneumocystis jirovecii pneumonia needed in patients with systemic autoimmune rheumatic diseases requiring immunosuppressive therapies?

  • Systematic Review
  • Published:
Rheumatology International Aims and scope Submit manuscript

Abstract

The incidence of Pneumocystis jirovecii pneumonia (PJP) has increased over recent years in patients with systemic autoimmune rheumatic diseases (SARD). PJP prognosis is poor in those receiving immunosuppressive therapy and glucocorticoids in particular. Despite the effectiveness of cotrimoxazole against PJP, the risk of adverse effects remains significant, and no consensus has emerged regarding the need for PJP prophylaxis in SARD patients undergoing immunosuppressor therapies.Objective: To evaluate the efficacy and safety of cotrimoxazole prophylaxis against PJP in SARD adult patients receiving immunosuppressive therapies. Methods: We performed a systematic review, consulting MEDLINE, EMBASE, and Cochrane Library databases up to April 2020. Outcomes covered prevention of PJP, other infections, morbidity, mortality, and safety. The information obtained was summarized with a narrative review and results were tabulated. Of the 318 identified references, 8 were included. Two were randomized controlled trials and six observational studies. The quality of studies was moderate or low. Despite disparities in the cotrimoxazole prophylaxis regimens described, results were consistent in terms of efficacy, particularly with glucocorticoid doses > 20 mg/day. However, cotrimoxazole 400 mg/80 mg/day, prescribed three times/ week, or 200 mg/40 mg/day or in dose escalation, exhibited similar positive performances. Conversely, cotrimoxazole 400 mg/80 mg/day showed higher incidences of withdrawals and adverse effects. Cotrimoxazole prophylaxis against PJP exhibited efficacy in SARD, mainly in patients taking glucocorticoids ≥ 20 mg/day. All cotrimoxazole regimens exposed seemed equally efficacious, although, higher quality trials are needed. Adverse effects were observed 2 months after initiation, particularly with the 400 mg/80 mg/day regimen. Conversely, escalation dosing or 200 mg/40 mg/day regimens appeared better tolerated.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1
Fig. 2

Similar content being viewed by others

References

  1. Thomas C, Limper A (2004) Pneumocystis pneumonia. N Engl J Med 350:2487–2498

    Article  CAS  Google Scholar 

  2. Park JW, Curtis JR, Moon J, Song YW, Kim S, Lee EB (2018) Prophylactic effect of trimethoprim-sulfamethoxazole for pneumocystis pneumonia in patients with rheumatic diseases exposed to prolonged high-dose glucocorticoids. Ann Rheum Dis 77(5):644–649

    Article  CAS  Google Scholar 

  3. Senanayake R, Mukhtar M (2013) Cotrimoxazole-induced hypoglycaemia in a patient with churg-strauss syndrome. Endocrinology. 2013:415810. https://doi.org/10.1155/2013/415810

    Article  Google Scholar 

  4. Cettomai D, Gelber A, Christopher-Stine L (2010) A survey of rheumatologists’ practice for prescribing pneumocystis prophylaxis. J Rheumatol 37:792–799

    Article  Google Scholar 

  5. Moher D, Liberati A, Tetzlaff J, Altman D (2010) Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. BMJ 8(336):341

    Google Scholar 

  6. López de Argumedo M, Reviriego E, Gutiérrez A, JC B (2017) Actualización del Sistema de Trabajo Compartido para Revisiones Sistemáticas de la Evidencia Científica y Lectura Crítica (Plataforma FLC 3.0). Ministerio de Sanidad, Servicios Sociales e Igualdad Servicio de Evaluación de Tecnologías Sanitarias del País Vasco

  7. Scottish Intercollegiate Guidelines Network (2011) SIGN 50, a guideline developer’s handbook. Edinburgh: SIGN; 2015 (SIGN publication no. 50). [November 2015]. Available from URL: http://www.sign.ac.uk

  8. Utsunomiya M, Dobashi H, Odani T et al (2017) Optimal regimens of sulfamethoxazole-trimethoprim for chemoprophylaxis of Pneumocystis pneumonia in patients with systemic rheumatic diseases: results from a non-blinded, randomized controlled trial. Arthritis Res Ther 19(1):7

    Article  Google Scholar 

  9. Yamamoto T, Hasunuma T, Takagi K et al (2014) A feasibility study assessing tolerability of daily versus twice weekly trimethoprim-sulfamethoxazole regimen for prophylaxis against pneumocystis pneumonia in patients with systemic autoimmune diseases on glucocorticoid therapy. Jpn J Clin Pharmacol Ther 45(3):89–92

    Article  CAS  Google Scholar 

  10. Maezawa R, Kurasawa K, Arai S, Okada H, Owada T, Fukuda T (2013) Positivity for anti-RNP antibody is a risk factor for adverse effects caused by trimethoprim-sulfamethoxazole, a prophylactic agent for P. jiroveci pneumonia, in patients with connective tissue diseases. Mod Rheumatol 23(1):62–70

    Article  Google Scholar 

  11. Ogawa J, Harigai M, Nagasaka K, Nakamura T, Miyasaka N (2005) Prediction of and prophylaxis against Pneumocystis pneumonia in patients with connective tissue diseases undergoing medium- or high-dose corticosteroid therapy. Mod Rheumatol 15(2):91–96

    Article  CAS  Google Scholar 

  12. Schmajuk G, Jafri K, Evans M, et al (2018) Pneumocystis jirovecii pneumonia (PJP) prophylaxis patterns among patients with rheumatic diseases receiving high-risk immunosuppressant drugs. Semin Arthritis Rheum 48(6):1087–1092. https://doi.org/10.1016/j.semarthrit.2018.10.018

  13. Takenaka K, Komiya Y, Ota M, Yamazaki H, Nagasaka K (2013) A dose-escalation regimen of trimethoprim-sulfamethoxazole is tolerable for prophylaxis against Pneumocystis jiroveci pneumonia in rheumatic diseases. Mod Rheumatol 23(4):752–758

    Article  CAS  Google Scholar 

  14. Vananuvat P, Suwannalai P, Sungkanuparph S, Limsuwan T, Ngamjanyaporn P, Janwityanujit S (2011) Primary prophylaxis for Pneumocystis jirovecii pneumonia in patients with connective tissue diseases. Semin Arthritis Rheum 41(3):497–502

    Article  Google Scholar 

  15. Meuli K, Chapman P, O’Donnell J, Frampton C, Stamp L (2007) Audit of pneumocystis pneumonia in patients seen by the Christchurch Hospital rheumatology service over a 5-year period. Intern Med J 37(10):687–692

    CAS  PubMed  Google Scholar 

  16. Braga BP, Prieto-Gonzalez S, Hernandez-Rodriguez J (2019) Pneumocystis jirovecii pneumonia prophylaxis in immunocompromised patients with systemic autoimmune diseases. Med Clin (Barc) 152(12):502–507. https://doi.org/10.1016/j.medcli.2019.01.010

  17. Godeau B, Coutant-Perronne V, Le Thi HD et al (1994) Pneumocystis carinii pneumonia in the course of connective tissue disease: report of 34 cases. J Rheumatol 21(2):246–251

    CAS  PubMed  Google Scholar 

  18. Grewal P, Brassard A (2009) Fact or fiction: does the non-HIV/AIDS immunosuppressed patient need Pneumocystis jiroveci pneumonia prophylaxis? An updated literature review. J Cutan Med Surg 13(6):308–312

    Article  Google Scholar 

  19. Cooley L, Dendle D, Wolf J, Teh BW, Chen SC, Boultis C (2014) Consensus guidelines for diagnosis, prophylaxis and management of Pneumocystis jirovecii pneumonia in patients with haematological and solid malignancies. Int Med J 44(1350):1363

    Google Scholar 

  20. Baulier G, Issa N, Gabriel F, Accoceberry I, Camou F, Duffau P (2018) Guidelines for prophylaxis of Pneumocystis pneumonia cannot rely solely on CD4-cell count in autoimmune and inflammatory diseases. Clin Exp Rheumatol 36(3):490–493

    PubMed  Google Scholar 

  21. Abe Y, Fujibayashi K, Nishizaki Y et al (2019) Conventional-dose versus half-dose sulfamethoxazole-trimethoprim for the prophylaxis of pneumocystis pneumonia in patients with systemic rheumatic disease: a non-blind. Randomized Controlled Trial Acta Med Okayama 73(1):85–89

    CAS  PubMed  Google Scholar 

  22. Matraiah EH, Olisaka N, Philipos M et al (2018) Late-onset Pneumocystis jirovecii pneumonia (PJP) in patients with ANCA-associated vasculitis. Clin Rheumatol 37(7):1991–1996

    Article  Google Scholar 

  23. Ward M, Donald F (1999) Pneumocystis carinii pneumonia in patients with connective tissue diseases: the role of hospital experience in diagnosis and mortality. Arthritis Rheum 42:780–789

    Article  CAS  Google Scholar 

  24. Ognibene FP, Shelhamer JH, Hoffman GS et al (1995) Pneumocystis carinii pneumonia: a major complication of immunosuppressive therapy in patients with Wegener’s granulomatosis. Am J Respir Crit Care Med 151(3 Pt 1):795–799

    CAS  PubMed  Google Scholar 

  25. Teichtahl AJ, Morrisroe K, Ciciriello S, Jennens I, Tadros S, Wicks I (2015) Pneumocystis jirovecci pneumonia in connective tissue diseases: comparison with other immunocompromised patients. Semin Arthritis Rheum 45(1):86–90

    Article  Google Scholar 

  26. Vallabhaneni S, Chiller TM (2016) Fungal infections and new biologic therapies. Curr Rheumatol Rep 18(5):29

    Article  Google Scholar 

  27. Kronbichler A, Jayne DR, Mayer G (2015) Frequency, risk factors and prophylaxis of infection in ANCA-associated vasculitis. Eur J Clin Invest 45(3):346–368

    Article  CAS  Google Scholar 

  28. Tasaka S (2020) Recent advances in the diagnosis and management of Pneumocystis pneumonia. Tuberc Respir Dis. 83(132):140

    Google Scholar 

  29. Caselli D, Petris MG, Rondelli R et al (2014) Single-day trimethoprim/sulfamethoxazole prophylaxis for Pneumocystis pneumonia in children with cancer. J Pediatr 164(2):389-392.e381

    Article  CAS  Google Scholar 

  30. Ramesh Prasad GV, Beckley J, Mathur M, Gunasekaran M, Nash MM, Rapi L (2019) Safety and efficacy of prophylaxis for Pneumocystis jirovecii pneumonia involving trimethoprim-sulfamethoxazole dose reduction in kidney transplantation. BMC Infect Dis 19:311

    Article  Google Scholar 

  31. Martin SL, Fishman JA (2013) Practice. aTAidCo. Pneumocystis pneumonia in solid organ transplantation. Am J Transplant 13:272–279

    Article  CAS  Google Scholar 

  32. Wolfe RM, Peacock JE Jr (2017) Pneumocystis pneumonia and the rheumatologist: which patients are at risk and how can PCP be prevented? Curr Rheumatol Rep 19(6):35

    Article  Google Scholar 

  33. Chung JB, Armstrong K, Schwartz JS, Albert D (2000) Cost-effectiveness of prophylaxis against Pneumocystis carinii pneumonia in patients with Wegner’s granulomatosis undergoing immunosuppressive therapy. Arthritis Rheum 43(8):1841–1848

    Article  CAS  Google Scholar 

  34. Soejima M, Sugiura T, Kawaguchi Y et al (2007) Association of the diplotype configuration at the N-acetyltransferase 2 gene with adverse events with co-trimoxazole in Japanese patients with systemic lupus erythematosus. Arthritis Res Ther 9(2):R23

    Article  Google Scholar 

  35. Smith CL, Brown I (1997) BM Torraca (1997) Acetylator status and tolerance of high-dose trimethoprim–sulfamethoxazole therapy among patients infected with human immunodeficiency virus. Clin Infect Dis. 25:1477–1478

    Article  CAS  Google Scholar 

  36. Belchi-Hernandez J, Espinosa-Parrra FJ (1996) Management of adverse reactions to prophylactic trimethoprim-sulfamethoxazole in patients with human immunodeficiency virus infection. Ann Allergy Asthma Immunol 76(355):358

    Google Scholar 

  37. Petri M, Allbritton J (1992) Antibiotic allergy in systemic lupus erythematosus: a case–control study. J Rheumatol 19(265):269

    Google Scholar 

Download references

Acknowledgements

The authors are grateful to Mercedes Guerra for her assistance in designing the reference search strategy and for performing primary reference selection, and to SER for revising the manuscript.

Funding

The present study was sponsored by the Spanish Society of Rheumatology (SER).

Author information

Authors and Affiliations

  1. Rheumatology Department, Hospital HLA Mediterráneo, Avenida Mediterráneo 353 bloque 2 4ºC, CP 04009, Almería, Spain

    C. A. Pereda

  2. Instituto Traumatológico Quirón Salud, Barcelona, Spain

    M. B. Nishishinya-Aquino

  3. Rheumatology Evidence Based Working Group, Spanish Society of Rheumatology, Madrid, Spain

    C. A. Pereda & M. B. Nishishinya-Aquino

  4. Research Unit, Spanish Society of Rheumatology, Madrid, Spain

    N. Brito-García & P. Díaz del Campo Fontecha

  5. Hospital de Gran Canaria Doctor Negrin, Las Palmas de Gran Canaria, Spain

    I. Rua-Figueroa

Authors
  1. C. A. Pereda
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. M. B. Nishishinya-Aquino
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. N. Brito-García
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. P. Díaz del Campo Fontecha
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. I. Rua-Figueroa
    View author publications

    You can also search for this author in PubMed Google Scholar

Contributions

CAP: visualization, writing—original draft lead, writing—review and editing. MBN-A: formal analysis, writing—original draft, writing—review and editing, lead. NB-G methodology, project administration, supervision. PDCF: conceptualization, investigation, supervision. IR-F writing—review and editing.

Corresponding author

Correspondence to C. A. Pereda.

Ethics declarations

Conflict of interest

Authors declare no conflicts of interest.

Additional information

Publisher's Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Supplementary Information

Below is the link to the electronic supplementary material.

Supplementary file1 (DOCX 22 KB)

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Pereda, C.A., Nishishinya-Aquino, M.B., Brito-García, N. et al. Is cotrimoxazole prophylaxis against Pneumocystis jirovecii pneumonia needed in patients with systemic autoimmune rheumatic diseases requiring immunosuppressive therapies?. Rheumatol Int 41, 1419–1427 (2021). https://doi.org/10.1007/s00296-021-04808-4

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s00296-021-04808-4

Keywords

Search

Navigation